Synageva BioPharma (GEVA) is out with an update on the development program for sebelipase alfa.
Enrollment is complete (and exceeded the target) in a Phase 3 trial in children and adults with LAL deficiency. Results expected in H2 2014.
Enrollment target met in Phase 2/3 trial in infants with LAL Deficiency. (PR)